Inhibition of Src with AZD0530 Reveals the Src-Focal Adhesion Kinase Complex as a Novel Therapeutic Target in Papillary and Anaplastic Thyroid Cancer
Rebecca E. Schweppe(University of Colorado Cancer Center), Bryan R. Haugen(University of Colorado Cancer Center)
Cited by 65
Related Papers
Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer
|Molecular Cancer|2014|102
Single-Dose Rexinoid Rapidly and Specifically Suppresses Serum Thyrotropin in Normal Subjects
|The Journal of Clinical Endocrinology & Metabolism|2006|53
Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor–Resistant Melanoma
|Molecular Cancer Therapeutics|2021|37
PPAR<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:mi mathvariant="bold">γ</mml:mi></mml:mrow></mml:math>Promotes Growth and Invasion of Thyroid Cancer Cells
|PPAR Research|2011|32
The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies
|Cancer Biology & Therapy|2024|7